Keyphrases
Immune-related Adverse Events
100%
Early-stage Triple-negative Breast Cancer
100%
Pembrolizumab
100%
Serum Biomarkers
100%
Nucleic Acid Programmable Protein Array (NAPPA)
60%
Autoantibodies
60%
Serum Samples
60%
Triple-negative Breast Cancer
60%
Clinical Application
40%
Breast Cancer
40%
Early Therapy
20%
Inefficacy
20%
Risk-benefit Ratio
20%
Toxicity Markers
20%
Predictors of Adverse Outcomes
20%
Breast Cancer Serum
20%
Immune Therapy Response
20%
Therapeutic Blockade
20%
Predictive Marker
20%
Registration Trial
20%
Anti-PD-1 Antibody Therapy
20%
Randomized Phase III Trial
20%
Profiling Technology
20%
Antibody Profiling
20%
Antibody Assay
20%
Cancer Causes
20%
Physician-scientist
20%
Validation Set
20%
Comprehensive Evaluation
20%
Human Proteins
20%
Biomarker Discovery
20%
Final Set
20%
Accurate Quantification
20%
Immune Checkpoint
20%
Potentially Toxic
20%
Tumor Immunity
20%
Clinically Significant
20%
High Risk
20%
Lessons Learned
20%
Anti-PD-1
20%
Immune System
20%
Adverse Effects
20%
Antibody Detection
20%
Outcome Information
20%
Cancer Types
20%
High-throughput
20%
Potential Predictors
20%
Malignancy
20%
Immune Checkpoint Therapy
20%
Adverse Events
20%
Positive Predictive Value
20%
Immunoproteomics
20%
Immune Response
20%
Patient Monitoring
20%
Cancer Mortality
20%
Tumor
20%
Medicine and Dentistry
Biological Marker
100%
Pembrolizumab
100%
Immune-Related Adverse Events
100%
Triple Negative Breast Cancer
100%
Protein Microarray
50%
Autoantibodies
50%
Nucleic Acid
50%
Adverse Event
33%
Immunotherapy
33%
Breast Cancer
33%
Cancer
33%
Immunity
33%
Immune System
16%
Immunoassay
16%
Predictive Marker
16%
Antibody Therapy
16%
Immune Response
16%
Cancer Mortality
16%
Risk-Benefit Ratio
16%
Patient Monitoring
16%
Adverse Effect
16%
Treatment Response
16%
Cancer Types
16%
Malignant Neoplasm
16%
Neoplasm
16%
Tumor Immunity
16%
Recurrent Disease
16%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Biological Marker
100%
Pembrolizumab
100%
Adverse Event
100%
Autoantibodies
42%
Nucleic Acid
42%
Malignant Neoplasm
28%
Neoplasm
28%
Breast Cancer
28%
Immunotherapy
28%
Recurrent Disease
14%
Immunoassay
14%
Cancer Mortality
14%